Wide Ranks

HUMAW

1.47

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 1.10 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 20 M Total Cash Per Share 0.1630 Total Debt 17 M
Total Debt To Equity Current Ratio 1.10 Book Value Per Share -0.5320
All Measures
Message Board Id finmb_107706507 City Durham Uuid 6bcadb08-5050-31d6-94a0-e272ec400e27
Previous Close 1.50 Book Value -0.5320 Beta 1.47
Total Debt 17 M Volume 35024 Fifty Two Week Low 1.45
Total Cash Per Share 0.1630 Max Age 86400 Sand P52 Week Change 0.3133
Net Income To Common -152867008 Trailing Peg Ratio None Total Cash 20 M
Trailing PE 0.0000 Regular Market Previous Close 1.50 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Open 1.55 Free Cashflow -58331500
State NC Dividend Yield 0.00 % Return On Assets -0.5323
Time Zone Short Name EST Trailing Eps -3.16 Day Low 1.45
Address1 2525 East North Carolina Highway 54 Target High Price 0.0000 Price Hint 4
Website https://www.humacyte.com Forward Eps 0.0000 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 98.20 % Is_sp_500 False
Regular Market Day High 1.64 Profit Margins 0.00 % Fifty Two Week High 1.64
Day High 1.64 Regular Market Open 1.55 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Operating Cashflow -90599000
Currency USD Time Zone Full Name America/New_York Is_nasdaq_100 False
Market Cap 0.0000 Zip 27713 Quote Type EQUITY
Industry Biotechnology Long Name Humacyte, Inc. Regular Market Day Low 1.45
Current Price 1.47 Financial Currency USD Current Ratio 1.10
Industry Disp Biotechnology Country United States Float Shares 91 M
Forward PE 0.0000 Regular Market Volume 35024 Ebitda -105277000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.

The company was founded in 2004 and is headquartered in Durham, North Carolina.